Valneva
Biotech

Why Valneva CEO remains bullish on Pfizer-partnered Lyme vaccine

Despite a phase 3 miss and a difficult regulatory environment, Valneva and Pfizer remain hopeful about scoring an approval for their Lyme disease shot.
Angus Liu Apr 1, 2026 3:00pm
Closeup of blue eye on black background

Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials

Apr 2, 2026 7:27am
Fierce Biotech43png

Scaling Radioligand Therapy: Expanding the Impact of Theranostics

Brought to you by Curium
colorful brain art model

Alto halts work on PDE4 inhibitor after ph. 2 schizophrenia fail

Apr 2, 2026 7:17am
cancelled flights

Gilead cancels HIV trial as clinical hold remains intact

Apr 1, 2026 4:50pm
Epia Neuro BCI

Epia launches to help stroke patients rework brain signals

Apr 2, 2026 10:00am
More News

Drug combo treats cancers with ‘paradox’ mutation in mice

Apr 1, 2026 2:00pm

Thousands of trial sites impacted by Middle East war: report

Apr 1, 2026 1:03pm

Alzheimer's-focused Korsana uses Cyclerion merger to go public

Apr 1, 2026 9:54am

Oric chases Pfizer into phase 3 hailing prostate cancer edge

Apr 1, 2026 9:53am